ArticleOrphanet journal of rare diseases2025
Economic burden of propionic acidemia in the United States: a claims-based study.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThere is currently no prior literature evaluating the economic burden of propionic acidemia (PA) in the US. This study evaluated the healthcare resource utilization (HRU) and expenditures associated with PA, overall and stratified by age.
methodsThe IQVIA PharMetrics® Plus Claims database was used to identify patients with PA and matched (1:1) non-PA control individuals, who were stratified into 0–2, 3–6, 7–12, 13–17, and 18 + years age strata. All-cause HRU and costs were compared between the 2 cohorts by age stratum; PA-related HRU/costs were described for patients with PA.
resultsAmong 230 paired observations across age strata, patients with PA had significantly higher all-cause HRU per-person-year (PPY) than control individuals. Patients with PA had 0.47–2.31 inpatient admissions PPY compared to 0.00-0.17 for control individuals (rate ratio: 10.36–78.55, all p < 0.001). Patients with PA had 2.23–4.46 times more emergency room visits and 1.89–8.21 times more outpatient visits than control individuals as assessed by rate ratios. Patients with PA incurred significantly higher annualized all-cause total healthcare costs than control individuals, with the highest difference in the 0–2 year old ($205,883) and the lowest in the 7–12 year old age stratum ($20,168; both p < 0.001). Among patients with PA, annualized mean PA-related total medical costs were $38,724 overall; inpatient admissions accounted for most costs ($33,575). Patients with PA who experienced metabolic decompensation events (MDEs) had higher HRU and costs than those without MDEs.
conclusionsPatients with PA, with or without MDEs, had significantly increased HRU and costs than matched controls without PA. Economic burden, largely driven by hospitalizations, was significantly higher among patients with PA than control individuals across all pediatric and adult age strata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.